Cosmo Pharmaceuticals N.V. (0RGI.L)
| Previous close | 48.73 |
| Open | 48.50 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 48.20 - 49.30 |
| 52-week range | 48.20 - 49.30 |
| Volume | |
| Avg. volume | N/A |
| Market cap | 714.46M |
| Beta (5Y monthly) | 1.00 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- EQS Group
Medtronic wins U.S. Department of Veterans Affairs contract to provide GI Genius™ intelligent endoscopy module for artificial intelligence (AI) assisted colon cancer screening
Cosmo Pharmaceuticals N.V. / Key word(s): MiscellaneousMedtronic wins U.S. Department of Veterans Affairs contract to provide GI Genius™ intelligent endoscopy module for artificial intelligence (AI) assisted colon cancer screening 06.10.2022 / 06:15 GMT/BSTDublin, Ireland – 06 October 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) announced today that Medtronic, its global partner for GI Genius™, published a media release that it has been awarded a contract for its Gastrointe
- EQS Group
Cosmo and InfectoPharm Announce Signing of License and Distribution Agreement for Winlevi® in Germany, Italy and Austria
Cosmo Pharmaceuticals N.V. / Key word(s): Agreement04-Oct-2022 / 06:00 GMT/BSTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Ad hoc announcement pursuant to Art. 53 LRDublin, Ireland & Heppenheim, Germany – 04 October 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) and InfectoPharm today announced the signing of a License and Distribution Agreement for Winlevi® (clascoterone) cream 1% in Germany, It
- EQS Group
Cosmo reports strong half-year 2022 financial results delivering record revenues and reaffirms 2022 full-year guidance
Cosmo Pharmaceuticals N.V. / Key word(s): Half Year Results28-Jul-2022 / 06:06 GMT/BSTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Ad hoc announcement pursuant to Art. 53 LRDublin, Ireland – 28 July 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced strong financial half-year 2022 results, with record revenue of €41.5 million up 46.1% (H1 2021: €28.4 million), EBITDA of €14.9 million
